Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Portfolio Pulse from Vandana Singh
Activist investor Starboard Value criticizes Pfizer for underperforming in R&D and overpaying for acquisitions, leading to a significant drop in stock value. Starboard highlights Pfizer's failure to meet its ambitious targets and concerns over its leveraged balance sheet, which could limit future growth.
October 22, 2024 | 5:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Starboard Value criticizes Pfizer for underperforming in R&D and overpaying for acquisitions, leading to a 50% stock drop since 2021. Concerns over Pfizer's leveraged balance sheet and failure to meet ambitious targets could impact future growth.
Starboard's criticism highlights significant issues with Pfizer's R&D and M&A strategies, which have not delivered expected returns. The stock has already dropped 50% since 2021, and concerns about a leveraged balance sheet could further impact investor confidence and stock performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100